Apyx Medical
Apyx Medical's revenue rose 9.9% to $53 million in fiscal 2025. Its operating margin was −12.2%, up from −39.2% a year earlier. Free cash flow was −$9 million. The diluted share count rose 15.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Apyx Medical does
Apyx Medical makes energy-based devices for surgeons. Its Renuvion products use helium plasma to deliver controlled heat to tissue, and plastic surgeons and cosmetic doctors use them mainly to tighten loose skin. The same technology is sold to hospitals as J-Plasma. AYON, a body contouring system cleared by the FDA in May 2025, combines fat removal with Renuvion's skin treatment; its full commercial launch began in September 2025.
The company has two segments. Surgical Aesthetics, which sells Renuvion, AYON and J-Plasma, brought in 85.8% of revenue in 2025. OEM, which makes generators and related devices for other medical device companies, brought in 14.2%, and Apyx expects that share to shrink as it focuses on aesthetics. With AYON it now competes with makers of liposuction devices such as Solta Medical, owned by Bausch Health, and MicroAire Surgical Instruments.
Apyx makes most of its products in Clearwater, Florida, and Sofia, Bulgaria, and had 205 full-time employees at the end of 2025. It launched Renuvion in China in July 2025, where it works through a joint venture it owns 51% of. It is losing money: in 2025 its loss from operations was $6.4 million, and it ended the year with $31.7 million in cash and cash equivalents.
Its biggest risks, as it describes them
- A history of operating losses, and the chance that it must raise more money or cut spending to keep operating.
- Its loan agreement requires it to meet revenue and spending targets, and missing them could hurt the business.
- Fewer people choosing cosmetic procedures, which they pay for themselves, would cut surgeons' demand for its products.
- Competition from larger, better-funded makers of energy-based aesthetic devices.
- Quality problems or product liability claims could lead to recalls, safety alerts and costly lawsuits.
Income statement
Apyx Medical lost money in fiscal 2025: a net loss of $11 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | — | 10 | 44 | 32 | 32 |
| Debt incl. finance leases | 0 | 0 | 33 | 38 | 38 |
| Net debt (negative means net cash) | — | −10 | −10 | 6 | 6 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 1.2x | 2.6x | 2.6x |
| Interest coverage | −1,444.8x | −1,570.8x | −7.0x | −3.2x | −1.1x |
| Current ratio | 4.6x | 3.6x | 5.5x | 5.3x | 5.0x |
| Quick ratio | 4.1x | 2.6x | 4.7x | 4.6x | 4.3x |
Cash flow
Projections
Project Apyx Medical's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Apyx Medical says to expect
- Full year 2026: Surgical Aesthetics revenue
Surgical Aesthetics revenue is expected to be in the range of $54.0 million to $55.0 million, compared with approximately $45.3 million reported for the year ended December 31, 2025.
- Full year 2026: gross margin
The Company expects gross margins in the range of 63% to 65%.
- Full year 2026: operating expenses
Total Company now expects operating expenses in the range of $41.0 million to $42.5 million for the year ended December 31, 2026 , down from the previous guidance of less than $45.0 million.
Insider trades
No officer, director or 10% owner of Apyx Medical reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 2 of 9 | 4 of 9 |
| Rule of 40 | 6.6% | −47.1% | −7.4% |
| Altman Z'' | 1.61 | −0.95 | −0.11 |
| Accruals ratio | −20.6% | −7.5% | −4.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Pass |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 3 of 9 | 2 of 9 | 4 of 9 |
Compare
Put Apyx Medical side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Apyx Medical | FY25 | 9.9% | −12.2% | −17.2% | −25.0% | — | 4 | |
| IRIDEX | FY25 | 8.2% | −4.9% | −4.3% | — | — | — | Compare |
| Carlsmed | FY25 | 85.9% | −60.5% | −58.6% | — | — | — | Compare |
| CVRx | FY25 | 10.4% | −90.5% | −71.9% | −294.3% | — | 3 | Compare |
| LENSAR | FY25 | 9.2% | −42.1% | −25.5% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 9 | 10 | 17 | 28 | 28 | 48 | 44 | 52 | 48 | 53 |
| Revenue growth | −70.1% | 16.0% | 62.2% | 70.0% | −1.9% | 75.1% | −8.3% | 17.6% | −8.1% | 9.9% |
| Gross profit | 5 | 7 | 11 | 19 | 18 | 34 | 29 | 34 | 29 | 33 |
| Research and development | 1 | 2 | 2 | 4 | 4 | 4 | 4 | 5 | 5 | 3 |
| Operating income | −11 | −14 | −14 | −21 | −20 | −14 | −24 | −17 | −19 | −6 |
| Net income | −12 | −5 | 63 | −20 | −12 | −15 | −23 | −19 | −24 | −11 |
| Diluted EPS (US$) | −0.15 | −0.17 | 1.83 | −0.58 | −0.35 | −0.44 | −0.67 | −0.54 | — | — |
| Diluted shares (millions) | 27 | 31 | 34 | 34 | 34 | 34 | 34 | 35 | 36 | 41 |
| Cash flow | ||||||||||
| Cash from operations | −3 | −4 | −21 | −18 | −16 | −10 | −20 | −5 | −18 | −8 |
| Capital expenditure | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
| Free cash flow | −3 | −4 | −21 | −20 | −17 | −11 | −21 | −6 | −19 | −9 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 1 | 2 | 4 | 4 | 5 | 7 | 5 | 4 | 2 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 14 | 10 | 78 | 59 | 82 | — | 10 | 44 | 32 | 32 |
| Debt incl. finance leases | 3 | 3 | 0 | 1 | 0 | 0 | 0 | 33 | 38 | 38 |
| Total assets | 35 | 31 | 96 | 85 | 74 | 69 | 52 | 79 | 65 | 67 |
| Total liabilities | 9 | 9 | 9 | 14 | 10 | 15 | 14 | 52 | 50 | 52 |
| Shareholders' equity | 26 | 22 | 87 | 71 | 64 | 54 | 38 | 27 | 14 | 14 |
| Margins and ratios | ||||||||||
| Gross margin | 58.0% | 68.0% | 65.2% | 67.6% | 63.2% | 69.3% | 65.5% | 64.5% | 61.0% | 62.5% |
| Operating margin | −129.2% | −135.7% | −86.0% | −73.9% | −72.5% | −29.8% | −52.9% | −33.0% | −39.2% | −12.2% |
| Net margin | −131.0% | −49.5% | 377.7% | −69.8% | −42.9% | −31.3% | −52.1% | −35.8% | −48.8% | −21.2% |
| Free cash flow margin | −35.4% | −42.3% | −127.9% | −70.0% | −60.1% | −23.0% | −47.8% | −11.1% | −39.0% | −17.2% |
| Rule of 40 (growth + FCF margin) | −105.5% | −26.2% | −65.7% | −0.0% | −61.9% | 52.1% | −56.1% | 6.6% | −47.1% | −7.4% |
| Return on capital | −68.1% | −74.4% | −95.2% | −149.9% | — | — | — | −61.6% | −81.2% | −25.0% |
| Return on equity | −46.5% | −21.0% | 114.9% | −24.9% | −17.6% | −25.8% | −50.8% | −58.2% | −114.7% | −78.0% |
| Return on assets | −34.7% | −15.3% | 98.8% | −21.8% | −15.0% | −21.2% | −38.5% | −28.6% | −32.6% | −17.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |